Skip to main content
Erschienen in: Journal of Cancer Survivorship 2/2014

01.06.2014

Fostering coordinated survivorship care in breast cancer: who is lost to follow-up?

verfasst von: Moshim Kukar, Nancy Watroba, Austin Miller, Shicha Kumar, Stephen B. Edge

Erschienen in: Journal of Cancer Survivorship | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Increasing numbers of cancer survivors and the recognition of their needs beyond recurrence surveillance are stretching resources at many cancer centers. Sometimes, patients solely follow up with providers other than the oncologist without coordinated care transfer plans. This study examines factors associated with transfer of breast cancer survivorship care outside one large cancer center.

Methods

Records on women with breast cancer diagnosed between July 1, 1997 and March 31, 2010 were linked to billing data through March 31, 2012 to identify the details of last oncology follow-up. A patient was classified as having transferred care outside the center if there was no oncology visit for more than 2 years. Clinical and pathologic characteristics were examined in a multivariate proportional hazards model to identify factors associated with transfer of care.

Results

Of 3,924 women with breast cancer, 858 (21.9 %) transferred care outside of our institution, 18 and 36 % at 5 and 10 years, respectively. Factors independently associated with transfer of care were age at diagnosis (unit increase 1.01/year age), stage IIA (HR 1.30, p = 0.02), longer driving distance to the cancer center (HR 1.65, p < 0.01), having had a cancer recurrence (HR 0.15 p < 0.01), and last visit in a medical oncology versus surgical oncology clinic (HR 0.32 p < 0.01).

Conclusions

Many patients with breast cancer do not continue oncology follow-up after treatment. Cancer programs should develop mechanisms to assist patients with care transfer and assure coordinated transfer to other providers to improve continuity of care.

Implications for Cancer Survivors

The results of this study will help the cancer centers identify the population of patients that are most likely to transfer care or become lost to follow up. Prospectively, identifying patients who may be more likely to transfer care will offer opportunities to effectively coordinate posttreatment surveillance with primary care.
Literatur
1.
Zurück zum Zitat Siegel R, Desantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220–41.CrossRefPubMed Siegel R, Desantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220–41.CrossRefPubMed
2.
Zurück zum Zitat Gage EA, Pailler M, Zevon MA, Ch'ng J, Groman A, Kelly M, et al. Structuring survivorship care: discipline-specific clinician perspectives. J Cancer Surviv. 2011;5:217–25.PubMedCentralCrossRefPubMed Gage EA, Pailler M, Zevon MA, Ch'ng J, Groman A, Kelly M, et al. Structuring survivorship care: discipline-specific clinician perspectives. J Cancer Surviv. 2011;5:217–25.PubMedCentralCrossRefPubMed
3.
4.
Zurück zum Zitat Rowland JH, Hewitt M, Ganz PA. Cancer survivorship: a new challenge in delivering quality cancer care. J Clin Oncol. 2006;24:5101–4.CrossRefPubMed Rowland JH, Hewitt M, Ganz PA. Cancer survivorship: a new challenge in delivering quality cancer care. J Clin Oncol. 2006;24:5101–4.CrossRefPubMed
5.
Zurück zum Zitat Rowland JH, Mariotto A, Alfano CM, Pollack LA, Weir HK, White A. Cancer survivors—United States, 2007. Morb Mortal Wkly Rep. 2011;60:269–72. Rowland JH, Mariotto A, Alfano CM, Pollack LA, Weir HK, White A. Cancer survivors—United States, 2007. Morb Mortal Wkly Rep. 2011;60:269–72.
6.
Zurück zum Zitat Hahn EE, Ganz PA, Melisko ME, Pierce JP, von Friederichs-Fitzwater M, Lane KT, et al. Provider perceptions and expectations of breast cancer posttreatment care: a University of California Athena Breast Health Network project. J Cancer Surviv 2013 Hahn EE, Ganz PA, Melisko ME, Pierce JP, von Friederichs-Fitzwater M, Lane KT, et al. Provider perceptions and expectations of breast cancer posttreatment care: a University of California Athena Breast Health Network project. J Cancer Surviv 2013
7.
Zurück zum Zitat Ganz PA. Survivorship: adult cancer survivors. Prim Care Clin Off Pract. 2009;36:721–41.CrossRef Ganz PA. Survivorship: adult cancer survivors. Prim Care Clin Off Pract. 2009;36:721–41.CrossRef
8.
Zurück zum Zitat Hewitt ME, Ganz P, Institute of Medicine (US), American Society of Clinical Oncology. From cancer patient to cancer survivor lost in transition. Washington, D.C., National Academies Press. Hewitt ME, Ganz P, Institute of Medicine (US), American Society of Clinical Oncology. From cancer patient to cancer survivor lost in transition. Washington, D.C., National Academies Press.
9.
Zurück zum Zitat Grunfeld E, Levine MN, Julian JA, Coyle D, Szechtman B, Mirsky D, et al. Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol. 2006;24:848–55.CrossRefPubMed Grunfeld E, Levine MN, Julian JA, Coyle D, Szechtman B, Mirsky D, et al. Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol. 2006;24:848–55.CrossRefPubMed
10.
Zurück zum Zitat Khan NF, Ward A, Watson E, Austoker J, Rose PW. Long-term survivors of adult cancers and uptake of primary health services: a systematic review. Eur J Cancer. 2008;44:195–204.CrossRefPubMed Khan NF, Ward A, Watson E, Austoker J, Rose PW. Long-term survivors of adult cancers and uptake of primary health services: a systematic review. Eur J Cancer. 2008;44:195–204.CrossRefPubMed
11.
Zurück zum Zitat Oeffinger KC, McCabe MS. Models for delivering survivorship care. J Clin Oncol. 2006;24:5117–24.CrossRefPubMed Oeffinger KC, McCabe MS. Models for delivering survivorship care. J Clin Oncol. 2006;24:5117–24.CrossRefPubMed
12.
Zurück zum Zitat Vanhuyse M, Bedard PL, Sheiner J, Fitzgerald B, Clemons M. Transfer of follow-up care to family physicians for early-stage breast cancer. Clin Oncol. 2007;19:172–6.CrossRef Vanhuyse M, Bedard PL, Sheiner J, Fitzgerald B, Clemons M. Transfer of follow-up care to family physicians for early-stage breast cancer. Clin Oncol. 2007;19:172–6.CrossRef
13.
14.
Zurück zum Zitat Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, et al. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res. 2012;14:R129.PubMedCentralCrossRefPubMed Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, et al. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res. 2012;14:R129.PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat de Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE, et al. Cancer survivors in the US: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev. 2013;22:561–70.PubMedCentralCrossRefPubMed de Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE, et al. Cancer survivors in the US: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev. 2013;22:561–70.PubMedCentralCrossRefPubMed
16.
Zurück zum Zitat Cheung WY, Aziz N, Noone AM, Rowland JH, Potosky AL, Ayanian JZ, et al. Physician preferences and attitudes regarding different models of cancer survivorship care: a comparison of primary care providers and oncologists. J Cancer Surviv 2013. Cheung WY, Aziz N, Noone AM, Rowland JH, Potosky AL, Ayanian JZ, et al. Physician preferences and attitudes regarding different models of cancer survivorship care: a comparison of primary care providers and oncologists. J Cancer Surviv 2013.
17.
Zurück zum Zitat Roorda C, Berendsen AJ, Haverkamp M, van der Meer K, de Bock GH Discharge of breast cancer patients to primary care at the end of hospital follow-up: A cross-sectional survey. Eur J Cancer 2013. Roorda C, Berendsen AJ, Haverkamp M, van der Meer K, de Bock GH Discharge of breast cancer patients to primary care at the end of hospital follow-up: A cross-sectional survey. Eur J Cancer 2013.
18.
Zurück zum Zitat Cowens-Alvarado R, Sharpe K, Pratt-Chapman M, Willis A, Gansler T, Ganz PA, et al. Advancing survivorship care through the National Cancer Survivorship Resource Center: Developing American Cancer Society Guidelines for Primary Care Providers. CA Cancer J Clin 2013. Cowens-Alvarado R, Sharpe K, Pratt-Chapman M, Willis A, Gansler T, Ganz PA, et al. Advancing survivorship care through the National Cancer Survivorship Resource Center: Developing American Cancer Society Guidelines for Primary Care Providers. CA Cancer J Clin 2013.
Metadaten
Titel
Fostering coordinated survivorship care in breast cancer: who is lost to follow-up?
verfasst von
Moshim Kukar
Nancy Watroba
Austin Miller
Shicha Kumar
Stephen B. Edge
Publikationsdatum
01.06.2014
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 2/2014
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-013-0323-5

Weitere Artikel der Ausgabe 2/2014

Journal of Cancer Survivorship 2/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.